BRISBANE, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that Peter Maag, PhD, CEO and President, and Ken Ludlum, Chief Financial Officer, will be presenting at the following upcoming investor conferences:
- The Jefferies 2015 Global Healthcare Conference in New York City on June 1, 2015 at 1:30pm PT/4:30pm ET.
- The JMP Life Sciences Conference in New York City on June 23, 2015 at 12:30pm PT/3:30pm ET.
A live audio webcast of these presentations will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of the presentations will begin approximately one hour after the conclusion of each live presentation and will be available on the Company's website for 90 days from the date of the respective presentation.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. The Company is currently investigating a research use only donor-derived cell-free DNA-based test for heart transplant recipients. For more information, please visit: www.CareDx.com.
CONTACT: Westwicke Partners, LLC Leigh J. Salvo Principal Tel: 415-513-1281 email@example.com